| Drug Type Small molecule drug | 
| Synonyms- | 
| Target | 
| Action modulators | 
| Mechanism CCL21 modulators(C-C motif chemokine ligand 21 modulators) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePreclinical | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Inflammation | Preclinical | Australia  | 19 Sep 2024 | |
| Lipid Metabolism, Inborn Errors | Preclinical | Australia  | 19 Sep 2024 | |
| Nervous System Diseases | Preclinical | Australia  | 19 Sep 2024 | 





